Drugs / Tomivosertib
Tomivosertib
also known as
eFT-508 · CPD 23 · EFT-508 HYDROCHLORIDE · eFT508HCl · TOMIVOSERTIB (EFT-508) · TOMIVOSERTIB HYDROCHLORIDE
Trials 9
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT05744739 | Sep 2023 → Jul 2024 | acute myeloid leukemia | Northwestern University | Terminated | No outcome recorded |
| Phase 1 | NCT04261218 | Aug 2020 → Jul 2022 | breast cancer | Translational Research in Oncology | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT02937675 | Feb 2017 → Nov 2018 | lymphoma | Effector Therapeutics | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1/2 | NCT02605083 | Dec 2015 → Jan 2019 | cancer | Effector Therapeutics | Terminated | No outcome recorded |
| Phase 25 trials | ||||||
| Phase 2 | NCT04622007 | Jun 2021 → Oct 2024 | non-small cell lung carcinoma | Effector Therapeutics | Unknown | No outcome recorded |
| Phase 2 | NCT03690141 | Nov 2018 → Apr 2020 | castration-resistant prostate carcinoma | Effector Therapeutics | Terminated | No outcome recorded |
| Phase 2 | NCT03616834 | Jul 2018 → Jan 2021 | cancer | Effector Therapeutics | Completed | No outcome recorded |
| Phase 2 | NCT03318562 | Nov 2017 → Jul 2018 | hepatocellular carcinoma, triple-negative breast carcinoma | Effector Therapeutics | Terminated | No outcome recorded |
| Phase 2 | NCT03258398 | Sep 2017 → Mar 2019 | colorectal cancer | Effector Therapeutics | Completed | No outcome recorded |
Evidence & citations 10 cited values
Every value below carries the sentence it was read from. 10 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Tomivosertib | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04622007 ↗ |
| Known as | CPD 23 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4073443 ↗ |
| Known as | eFT-508 | “Tomivosertib (eFT-508) is a novel, small-molecule investigational drug being developed by eFFECTOR Therapeutics” NCT03616834 ↗5“evaluating the safety, pharmacokinetics, pharmacodynamics, and antitumor activity of Tomivosertib (eFT-508)” NCT02937675 ↗ |
| Known as | EFT-508 HYDROCHLORIDE | ChEMBL registry synonym — accepted as the source's own label CHEMBL4073443 ↗ |
| Known as | eFT508HCl | ChEMBL registry synonym — accepted as the source's own label CHEMBL4073443 ↗ |
| Known as | TOMIVOSERTIB (EFT-508) | ChEMBL registry synonym — accepted as the source's own label CHEMBL4073443 ↗ |
| Known as | TOMIVOSERTIB HYDROCHLORIDE | ChEMBL registry synonym — accepted as the source's own label CHEMBL4073443 ↗ |
| Action | Inhibit | “eFT508 is an oral, potent and highly selective inhibitor of mitogen-activated protein kinase interacting kinase (MNK) 1 and 2.” NCT02605083 ↗ |
| Modality | Small molecule | “small-molecule investigational drug” NCT03616834 ↗ |
| Route | Oral | “Will be given orally once or twice daily.” NCT02605083 ↗ |